 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...112113114115116117118119120121122123124» |
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: HOPE: Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (clinicaltrials.gov) - Apr 1, 2016
P2, N=39, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers (clinicaltrials.gov) - Mar 30, 2016
P1, N=60, Completed, Sponsor: Eisai Inc.
- || golvatinib (E7050) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) (clinicaltrials.gov) - Mar 28, 2016
P1/2, N=226, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Feb 2017 --> Mar 2015
- ||||| New P1/2 trial, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Mar 25, 2016
P1/2, N=70, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - Mar 16, 2016
P2, N=182, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Feb 2017 --> Mar 2015 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Apr 2013
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Mar 8, 2016
P2, N=210, Not yet recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 21, 2016
P1, N=18, Recruiting, Sponsor: Eisai Inc.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments (clinicaltrials.gov) - Feb 18, 2016
P2, N=135, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Apr 2013 Trial primary completion date: Dec 2015 --> Oct 2013
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: TALENT: Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 10, 2016
P2, N=110, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Enrollment change, Metastases: A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) - Jan 19, 2016
P2, N=37, Completed, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Dec 2015 --> Oct 2013 Active, not recruiting --> Completed | N=16 --> 37
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jan 19, 2016
P1, N=7, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed | N=16 --> 37 Recruiting --> Active, not recruiting | N=12 --> 7
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) (clinicaltrials.gov) - Jan 15, 2016
P2, N=76, Not yet recruiting, Sponsor: Eisai Inc.
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Dec 29, 2015
P2, N=39, Not yet recruiting, Sponsor: Virginia G. Kaklamani
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Enrollment open, Metastases: Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (clinicaltrials.gov) - Nov 28, 2015
P=N/A, N=25, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=12 --> 7 Not yet recruiting --> Recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=99, Recruiting, Sponsor: Eisai Limited
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Nov 6, 2015
P1/2, N=99, Active, not recruiting, Sponsor: Eisai Limited
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (clinicaltrials.gov) - Nov 3, 2015
P2, N=25, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
New trial, Metastases: Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (clinicaltrials.gov) - Oct 30, 2015
P=N/A, N=25, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial primary completion date: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Oct 22, 2015
P2, N=20, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting N=1000 --> 20 | Trial primary completion date: Nov 2015 --> Feb 2016
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (clinicaltrials.gov) - Oct 22, 2015
P2, N=25, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. (clinicaltrials.gov) - Oct 22, 2015
P1, N=6, Completed, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Sep 29, 2015
P2, N=40, Not yet recruiting, Sponsor: National University Hospital, Singapore
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 8, 2015
P3, N=954, Active, not recruiting, Sponsor: Eisai Limited
N=1000 --> 20 | Trial primary completion date: Nov 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Aug 15, 2015
P1/2, N=150, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Jul 17, 2015
P1/2, N=150, Not yet recruiting, Sponsor: Eisai Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Combination therapy, Metastases: A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma (clinicaltrials.gov) - Jul 6, 2015
P1, N=115, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jun 26, 2015
P1, N=12, Recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jun 22, 2015
P1/2, N=66, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2014
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) (clinicaltrials.gov) - May 30, 2015
P=N/A, N=400, Recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2014 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 27, 2015
P1, N=12, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg) (clinicaltrials.gov) - May 5, 2015
P1, N=14, Completed, Sponsor: Eisai Inc.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - May 4, 2015
P1/2, N=99, Recruiting, Sponsor: Eisai Limited
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) - Apr 8, 2015
P2, N=16, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Mar 12, 2015
P1/2, N=66, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Dec 2015
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors (clinicaltrials.gov) - Mar 7, 2015
P1, N=30, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Mar 2009 --> Sep 2008
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2015
P1, N=18, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Mar 2009 --> Sep 2008 Initiation date: Nov 2010 --> Feb 2011
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments (clinicaltrials.gov) - Feb 5, 2015
P2, N=135, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Nov 2010 --> Feb 2011 Trial primary completion date: Oct 2013 --> Dec 2015
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) - Jan 28, 2015
P2, N=167, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Oct 2013 --> Dec 2015 Trial primary completion date: Jun 2014 --> May 2012
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: An Open Label Dose Escalation Study Of E7080 (clinicaltrials.gov) - Jan 28, 2015
P1, N=82, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2014 --> May 2012 Trial primary completion date: Jun 2014 --> Jun 2009
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma (clinicaltrials.gov) - Jan 28, 2015
P1, N=115, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2014 --> Jun 2009 Completed --> Active, not recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Dec 19, 2014
P2, N=1000, Recruiting, Sponsor: Eisai Co., Ltd.
Completed --> Active, not recruiting Trial primary completion date: Sep 2014 --> Nov 2015
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (clinicaltrials.gov) - Dec 19, 2014
P3, N=392, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Sep 2014 --> Nov 2015 Trial primary completion date: Jan 2015 --> Nov 2013
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=16, Recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Jan 2015 --> Nov 2013 Trial primary completion date: Aug 2014 --> Jun 2015
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 30, 2014
P3, N=940, Recruiting, Sponsor: Eisai Limited
Trial primary completion date: Aug 2014 --> Jun 2015 Trial primary completion date: Feb 2015 --> Apr 2016
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial primary completion date: Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (clinicaltrials.gov) - Aug 8, 2014
P2, N=116, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Feb 2015 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2011 --> Apr 2011
- lenvatinib / Generic mfg.
Clinical: An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=0, Available, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers (clinicaltrials.gov) - Jul 24, 2014
P1, N=15, Completed, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects (clinicaltrials.gov) - Jul 24, 2014
P1, N=26, Completed, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers (clinicaltrials.gov) - Jul 23, 2014
P1, N=18, Completed, Sponsor: Eisai Inc.